This week, researchers from the Dana-Farber Cancer Institute collaborated with the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR) to release recommendations for increasing the representation of African American patients in clinical trials for multiple myeloma (MM). To develop these recommendations, researchers, providers, patients, and industry partners came together with regulators at an FDA-AACR sponsored workshop to outline a “roadmap” to improved enrollment.
According to a systematic review published in JCO Global Oncology, delays and interruptions in cancer care as a result of the COVID-19 pandemic affected many patients. The study authors called the frequency of delays “remarkable, showing a relevant impact of the pandemic on the care of patients with cancer.” They added, “From now and on the basis of these findings, strategies can be proposed to mitigate the main delays and disruptions.”
Results from the phase 3 HERO trial recently demonstrated superior suppression of testosterone levels with relugolix compared to leuprolide with fewer major adverse cardiovascular events in men with advanced prostate cancer. In a poster presented during the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium, the investigators presented a subgroup analysis from the trial of 125 patients who received concomitant prostate cancer treatments showing relugolix maintained similar efficacy in this group.
A model found that rates of pancreatic cancer mortality were not predicted to improve across Europe in 2021 and may even increase among women. Using this data, which was published in the Annals of Oncology, the research team have called on European health care policymakers to invest in resources to improve diagnosis and treatment of pancreatic cancer to improve these numbers.